| 产品描述: | YKL-5-124 是一种有效的、选择性不可逆 CDK7 共价抑制剂,对 CDK7 和 CDK7/Mat1/CycH 的 IC50 分别为 53.5 nM 和 9.7 nM。YKL-5-124 对 CDK7 的选择性比 CDK9 和 CDK2 高 100 倍以上,并且对 CDK12 和 CDK13 没有活性。YKL-5-124 诱导强烈的细胞周期停滞,并抑制 E2F 驱动的基因表达,并且对 RNA 聚合酶 II 磷酸化状态几乎没有影响。 |
| 靶点: |
CDK7 53.5 nM (IC50);CDK7/Mat1/CycH 9.7 nM (IC50);CDK2 1300 nM (IC50);CDK9 3020 nM (IC50);CDK |
| 体外研究: |
YKL-5-124 (0-2000 nM; 72 hours; HAP1 cells) treatment causes a dose-dependent increase in G1- and G2/M-phase cells and a corresponding loss of S-phase cells. YKL-5-124 (0-2000 nM; 24 hours; HAP1 WT cells) treatment inhibits CDK1 T-loop phosphorylation, and to a lesser extent CDK2 T-loop phosphorylation in a concentration-dependent fashion. Treatment of cells with YKL-5-124 as a competitor at a concentration of about 30 nM blocks pull-down of CDK7-cyclin H but has no effect on the pull-down of cyclin K-CDK12/13 in HAP1 cells. Treatment with 100 nM YKL-5-124 reduces CDK7-cyclin H binding to bioTHZ1 by >50% at 30 min. |
| 参考文献: |
1.Olson CM, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019 Jun 20;26(6):792-803.e10. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.939 ml |
9.697 ml |
19.395 ml |
| 5 mM |
0.388 ml |
1.939 ml |
3.879 ml |
| 10 mM |
0.194 ml |
0.97 ml |
1.939 ml |
| 50 mM |
0.039 ml |
0.194 ml |
0.388 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |